Correlation of MMP2-C1306T (rs243865) and MMP7-181A/G (rs11568818) with cervical cancer: a meta-analysis

Objective: We aimed to determine whether a correlation exists between the polymorphisms of matrix metalloproteinases (MMPs) MMP2-C1306T (rs243865) and MMP7-181A/G (rs11568818) and cervical cancer (CC). Methods: A literature search up to September 28, 2018, in PubMed, the Cochrane Library, and Embase was conducted. Odds ratio (OR) and 95% confidence interval (CI) were used as effect models. The quality, heterogeneity, and publication bias of the included studies were assessed. Results: Five studies with a total of 1,630 participants were included. For the G vs. A and GG vs. AA model of the rs11568818 gene, no significant heterogeneity was found (p < 0.05, I ² > 50%). No statistical significance was found for all the rs243865 models, indicating no significant association between rs243865 and CC. The meta-analysis of the rs11568818 gene polymorphism revealed a statistical significance for G vs. A (OR = 1.3719; 95% CI, 1.1480-1.6395; P = 0.0005), GG vs. AA (OR = 1.8561; 95% CI, 1.2682-2.7165; P = 0.0015), and GG vs. AA+GA (OR = 1.7448; 95% CI, 1.0104-3.0130; P = 0.0458). No publication bias was found for all the rs11568818 and rs243865 models, which suggested that the present results were reliable. Conclusions: MMP7-181A/G (rs11568818) was associated with CC; however, MMP2-C1306T (rs243865) was not associated with CC.

Cervical cancer; Gene polymorphism; Matrix metalloproteinases; Meta-analysis

[1] Irizarry R.A., Wu Z., Jaffee H.A.: “Comparison of Affymetrix GeneChip expression measures”. Bioinformatics, 2006, 22, 789.

[2] Schiffman M., Wentzensen N., Wacholder S., Kinney W., Gage J.C., Castle P.E.: “Response: Re: Human Papillomavirus Testing in the Prevention of Cervical Cancer”. Cancerspectrum Knowledge Environment, 2011, 103, 368.

[3] Uyar D., Rader J.: “Genomics of cervical cancer and the role of human papillomavirus pathobiology”. Clin. Chem., 2014, 60, 144.

[4] Yang M., Zhu H., Hu T., Liu S., Wang H.: “Association of CCND1 gene polymorphism with cervical cancer susceptibility in Caucasian population: a meta-analysis”. Int. J. Clin. Exp. Med., 2015, 8, 12983.

[5] Verma R.P., Hansch C.: “Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs”. Bioorg. Med. Chem., 2007, 15, 2223.

[6] Liu D., Guo H., Li Y., Xu X., Yang K., Bai Y.: “Association be- tween polymorphisms in the promoter regions of matrix metallo-proteinases (MMPs) and risk of cancer metastasis: a meta-analysis”. Plos One, 2012, 7, e31251.

[7] Mccolgan P., Sharma P.: “Polymorphisms of matrix metalloproteinases 1, 2, 3 and 9 and susceptibility to lung, breast and colorectal cancer in over 30,000 subjects”. Int. J. Cancer, 2010, 125, 1473.

[8] Peng B., Cao L., Ma X., Wang W., Wang D., Yu L.: “Meta-analysis of association between matrix metalloproteinases 2, 7 and 9 promoter polymorphisms and cancer risk”. Mutagenesis, 2010, 25, 371.

[9] Rauvala M., Aglund K., Puistola U., Turpeenniemi-Hujanen T., Hor-vath G., Willén R., Stendahl U.: “Matrix metalloproteinases- 2 and - 9 in cervical cancer: different roles in tumor progression”. Int. J. Gynecol. Cancer, 2010, 16, 1297.

[10] Tao H.J., Su-Hui W.U., Zhang L.I., Lin W.F., Na L.U., Fan J., et al.: “Correlation of polymorphism of IL-8 and MMP-7 genes with the risk of early stage cervical cancer in Shanxi”. Chinese Remedies & Clinics, 2010.

[11] Xie B., Zhang Z., Wang H., Chen Z., Wang Y., Liang H., et al.: “Genetic polymorphisms in MMP 2, 3, 7, and 9 genes and the susceptibility and clinical outcome of cervical cancer in a Chinese Han population”. Tumor Biol., 2016, 37, 4883.

[12] Singh N., Hussain S., Sharma U., Suri V., Nijhawan R., Bharadwaj M., et al.: “The protective role of the -1306C>T functional polymorphism in matrix metalloproteinase-2 gene is associated with cervical cancer: implication of human papillomavirus infection”. Tumour Biol., 2016, 37, 5295.

[13] Wu Suhui, Lu Shi, Tao Huijuan, Zhang Li, Lin Weifeng, Shang Haixia, et al.: “Correlation of Polymorphism of IL-8 and MMP-7 withOccurrence and Lymph Node Metastasis of Early Stage Cervical Cancer”. Journal of Huazhong University of Science and Technology (Medical Sciences), 2011, 31, 114-9.

[14] Stang A.: “Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses”. Eur. J. Epidemiol., 2010, 25, 603.

[15] Schaid D.J., Jacobsen S.J.: “Biased tests of association: comparisons of allele frequencies when departing from Hardy-Weinberg proportions”. Am. J. Epidemiol., 2001, 154, 287.

[16] Liu T., Xu Q.E., Zhang C.H., Zhang P.: “Occupational exposure to methylene chloride and risk of cancer: a meta-analysis”. Cancer Causes Control, 2013, 24, 2037.

[17] Lau J., Ioannidis J.P., Schmid C.H.: “Quantitative synthesis in systematic reviews”. Ann. Internal Med., 1997, 127, 820.

[18] Feng R.N., Chen Z., Sun C.H., Ying L.: “Meta-Analysis ofTNF308 G/A Polymorphism and Type 2 Diabetes Mellitus”. Plos One, 2011, 6, e18480.

[19] Vandenbroucke J.P.: “Bias in meta-analysis detected by a simple, graphical test. Experts’ views are still needed”. BMJ, 1997, 316, 469.

[20] Singh H., Jain M., Mittal B.: “MMP-7 (-181A>G) promoter polymorphisms and risk for cervical cancer”. Gynecol. Oncol., 2008, 110, 71.

[21] Baltazar-Rodriguez L.M., Anaya-Ventura A., Andrade-Soto M., Monrroy-Guizar E.A., Bautista-Lam J.R., Jonguitud-Olguin G., et al.: “Polymorphism in the Matrix Metalloproteinase-2 Gene Promoter is Associated with Cervical Neoplasm Risk in Mexican Women”. Biochem. Gen., 2008, 46, 137.

[22] Yach D.: “Meta-analysis in epidemiology”. S. Afr. Med. J., 1990, 78, 94.

[23] O-Charoenrat P., Khantapura P.: “The role of genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes in head and neck cancer”. Oral Oncol., 2006, 42, 257.

[24] Yao N.: “Correlation of polymorphism of MMP-7 gene with the risk of early stage cervical cancer”. China J. Modern Med., 2011, 21, 3519.

[25] Wang C., Hua L.I., Zong Y.G., Lou Y.T., Zhang H.G.: “Association between gene polymorphism of MMP7 promoter region and colorectal cancer”. J. Harbin Med. University, 2015.

[26] Yi Y.C., Chou P.T., Chen L.Y., Kuo W.H., Ho E.S., Han C.P., et al.: “Matrix metalloproteinase-7 (MMP-7) polymorphism is a risk factor for endometrial cancer susceptibility”. Clin. Chem. Lab. Med., 2010, 48, 337.

[27] Adabi Z., Mohsen S.Z., Imani M., Samzadeh M., Narouie B., Jamaldini S.H., et al.: “Genetic Polymorphism of MMP2 Gene and Susceptibility to Prostate Cancer”. Arch .Med. Res., 2015, 46, 546.

[28] Zhu W., Jiang C.: “Meta analysis on gene polymorphism of Matrix metalloproteinase-1,-7 in promoter regions and the susceptibility of cervical cancer”. Inte. J. Lab. Med., 2016.

[29] Jormsjö S., Whatling C., Walter D.H., Zeiher A.M., Ham- sten A., Eriks- son P.: “Allele-specific regulation of matrix metalloproteinase-7 promoter activity is associated with coronary artery luminal dimensions among hypercholesterolemic patients”. Arteriosclerthrombvascbiol., 2001, 21, 1834.